Product Pathways - Ca / cAMP / Lipid Signaling
PKCι (C83H11) Rabbit mAb #2998
|2998S||100 µl (10 western blots)||---||In Stock||---|
|2998||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
|W||1:1000||Human, Mouse, Rat, Monkey||Endogenous||78||Rabbit IgG|
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting, F=Flow Cytometry
Specificity / Sensitivity
PKCι (C83H11) Rabbit mAb detects endogenous levels of total PKCι. The antibody does not cross-react with other PKC isoforms.
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to human PKCι.
Western blot analysis of extracts from C2C12, PC12 and COS cells using PKCι (C83H11) Rabbit mAb.
Activation of protein kinase C (PKC) is one of the earliest events in a cascade that controls a variety of cellular responses, including secretion, gene expression, proliferation, and muscle contraction (1,2). PKC isoforms belong to three groups based on calcium dependency and activators. Classical PKCs are calcium-dependent via their C2 domains and are activated by phosphatidylserine (PS), diacylglycerol (DAG), and phorbol esters (TPA, PMA) through their cysteine-rich C1 domains. Both novel and atypical PKCs are calcium-independent, but only novel PKCs are activated by PS, DAG, and phorbol esters (3-5). Members of these three PKC groups contain a pseudo-substrate or autoinhibitory domain that binds to substrate-binding sites in the catalytic domain to prevent activation in the absence of cofactors or activators. Control of PKC activity is regulated through three distinct phosphorylation events. Phosphorylation occurs in vivo at Thr500 in the activation loop, at Thr641 through autophosphorylation, and at the carboxy-terminal hydrophobic site Ser660 (2). Atypical PKC isoforms lack hydrophobic region phosphorylation, which correlates with the presence of glutamic acid rather than the serine or threonine residues found in more typical PKC isoforms. The enzyme PDK1 or a close relative is responsible for PKC activation. A recent addition to the PKC superfamily is PKCμ (PKD), which is regulated by DAG and TPA through its C1 domain. PKD is distinguished by the presence of a PH domain and by its unique substrate recognition and Golgi localization (6). PKC-related kinases (PRK) lack the C1 domain and do not respond to DAG or phorbol esters. Phosphatidylinositol lipids activate PRKs, and small Rho-family GTPases bind to the homology region 1 (HR1) to regulate PRK kinase activity (7).
PKCι (iota) is an atypical PKC that has recently been identified as an oncogene. The corresponding gene is amplified in many types of cancer and protein expression is essential for transformed cell growth, making this protein an attractive therapeutic target (8).
- Nishizuka, Y. (1984) Nature 308, 693-8.
- Keranen, L.M. et al. (1995) Curr Biol 5, 1394-1403.
- Mellor, H. and Parker, P.J. (1998) Biochem J 332 ( Pt 2), 281-92.
- Ron, D. and Kazanietz, M.G. (1999) FASEB J 13, 1658-76.
- Moscat, J. and Diaz-Meco, M.T. (2000) EMBO Rep 1, 399-403.
- Baron, C.L. and Malhotra, V. (2002) Science 295, 325-8.
- Flynn, P. et al. (2000) J Biol Chem 275, 11064-70.
- Fields, A.P. and Regala, R.P. (2007) Pharmacol. Res. 55, 487-497.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
- 2056 PKCα Antibody
- 2058 PKCδ Antibody
- 2683 PKCε (22B10) Rabbit mAb
- 9368 PKCζ (C24E6) Rabbit mAb
- 9372 PKCζ Antibody
- 2052 PKD/PKCμ Antibody
- 7071 Phototope®-HRP Western Blot Detection System, Anti-rabbit IgG, HRP-linked Antibody
- 7074 Anti-rabbit IgG, HRP-linked Antibody
- 7720 Prestained Protein Marker, Broad Range (Premixed Format)
- 7727 Biotinylated Protein Ladder Detection Pack
- 7003 20X LumiGLO® Reagent and 20X Peroxide
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
This antibody is developed, validated, and produced by CST using in part technology under license (granting certain rights including those under U.S. Patent No. 5,675,063) from Epitomics, Inc.